Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
November 14, 2024 07:15 ET
|
Appili Therapeutics Inc.
Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal...
Appili Therapeutics Announces Results of Special Meeting of Shareholders
November 06, 2024 17:55 ET
|
Appili Therapeutics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
October 31, 2024 07:15 ET
|
Appili Therapeutics Inc.
Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for...
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
October 17, 2024 07:15 ET
|
Appili Therapeutics Inc.
ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine candidate ATI-1701 and present new data on efficacy ...
Appili Therapeutics – Press Release Correction
October 10, 2024 15:40 ET
|
Appili Therapeutics Inc.
HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), announces correction to its press release entitled “Appili...
Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders
October 10, 2024 07:13 ET
|
Appili Therapeutics Inc.
Your vote is important no matter how many votes you hold.Shareholders who have questions or need assistance with voting their shares should contact info@appilitherapeutics.com HALIFAX, Nova Scotia,...
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
September 17, 2024 17:11 ET
|
Appili Therapeutics Inc.
HALIFAX, Nova Scotia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for...
Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt
August 21, 2024 07:15 ET
|
Appili Therapeutics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025
August 13, 2024 17:19 ET
|
Appili Therapeutics Inc.
Definitive agreement with Aditxt, if approved by Appili shareholders, provides significant premium to shareholders and resources to advance key programs ATI-1701 funding commitments from U.S. Air...
Appili Therapeutics Announces Second Amendment to Arrangement Agreement
July 18, 2024 17:07 ET
|
Appili Therapeutics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...